Cara Therapeutics Reports Third Quarter 2023 Financial Results
November 13, 2023 16:01 ET
|
Cara Therapeutics, Inc.
– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 – – Key data readouts for all three late-stage oral difelikefalin clinical...
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
November 02, 2023 07:00 ET
|
Cara Therapeutics, Inc.
Transaction supports progression of late-stage oral difelikefalin clinical programs Non-dilutive capital expected to extend cash runway into 2025 STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) --...
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
October 23, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
September 25, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Reports Second Quarter 2023 Financial Results
August 07, 2023 16:01 ET
|
Cara Therapeutics, Inc.
– 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company’s share of profit of KORSUVA® (difelikefalin) injection – – Demand for KORSUVA injection accelerating with 46%...
Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors
August 03, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
July 24, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...